Boehringer Ingelheim, GSK, Novartis, Teva, and Covis Pharma have been taken to task for asthma and COPD inhalers, while Amphastar Pharma has been warned over its Baqsimi glucagon nasal spray ...

Glucagon is a recognised therapy for the ... 2019 as a hypoglycaemia rescue therapy for diabetics. Eli Lilly's nasal spray Baqsimi was also approved in 2019 for a similar indication.

Amphastar Pharmaceuticals' stock has declined over 25% since early November, despite solid earnings and sales growth. Click ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...